A detailed history of Geode Capital Management, LLC transactions in Protara Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 170,040 shares of TARA stock, worth $916,515. This represents 0.0% of its overall portfolio holdings.

Number of Shares
170,040
Previous 140,526 21.0%
Holding current value
$916,515
Previous $292,000 6.51%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$1.7 - $2.4 $50,173 - $70,833
29,514 Added 21.0%
170,040 $311,000
Q2 2024

Aug 09, 2024

BUY
$1.96 - $4.14 $112,933 - $238,542
57,619 Added 69.5%
140,526 $292,000
Q1 2024

May 13, 2024

BUY
$1.86 - $4.83 $8,163 - $21,198
4,389 Added 5.59%
82,907 $332,000
Q3 2023

Nov 13, 2023

SELL
$1.64 - $2.93 $8,039 - $14,362
-4,902 Reduced 5.88%
78,518 $131,000
Q4 2022

Feb 13, 2023

SELL
$2.43 - $3.7 $544 - $828
-224 Reduced 0.27%
83,420 $223,000
Q2 2022

Aug 12, 2022

BUY
$2.8 - $5.33 $4,704 - $8,954
1,680 Added 2.05%
83,644 $245,000
Q1 2022

May 13, 2022

BUY
$4.19 - $6.9 $12,347 - $20,334
2,947 Added 3.73%
81,964 $418,000
Q3 2021

Nov 12, 2021

SELL
$6.38 - $9.3 $25,315 - $36,902
-3,968 Reduced 4.78%
79,017 $546,000
Q2 2021

Aug 13, 2021

SELL
$8.68 - $16.99 $243,708 - $477,028
-28,077 Reduced 25.28%
82,985 $808,000
Q1 2021

May 12, 2021

BUY
$13.75 - $23.86 $85,002 - $147,502
6,182 Added 5.89%
111,062 $1.75 Million
Q4 2020

Feb 12, 2021

BUY
$16.97 - $25.34 $1.44 Million - $2.14 Million
84,598 Added 417.11%
104,880 $2.54 Million
Q3 2020

Nov 13, 2020

BUY
$16.76 - $31.89 $47,564 - $90,503
2,838 Added 16.27%
20,282 $341,000
Q2 2020

Aug 13, 2020

BUY
$22.0 - $60.7 $383,768 - $1.06 Million
17,444 New
17,444 $511,000

Others Institutions Holding TARA

About Protara Therapeutics, Inc.


  • Ticker TARA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 11,267,400
  • Market Cap $60.7M
  • Description
  • Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chlorid...
More about TARA
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.